Dr. Sokoloff is internationally recognized for his contributions to the treatment of urologic cancers. He has particular expertise in the management of prostate, kidney, and testes cancers. He performs nerve-sparing robotic and conventional prostatectomies for prostate cancer and nephron-sparing partial nephrectomies for kidney cancer. He is trained in and utilizes laparoscopic and robotic techniques whenever possible.
Dr. Sokoloff was Director or Urologic Oncology at the University of Chicago where he created a highly acclaimed translational and clinical trial research program – taking findings from his laboratory and applying them to the care of patients with urologic caners not generally amenable to cure with surgery alone. Dr. Sokoloff has received support from the Department of Defense and the National Cancer institute for this research. He was also instrumental in initiating innovative potency-preservation and robotic prostatectomy programs as well as expanding the laparoscopic kidney cancer program.
At OHSU, where Dr. Sokoloff was chief of the Section of Urologic Oncology and Director of Robotic Surgery, he rebuilt and expanded the urologic cancer program by augmenting the surgical practice to include the addition of innovative systemic therapies to target locally advanced, metastatic, and high-risk tumors as well as incorporating robotic and other minimally invasive technologies into daily practice
In 2008, Dr. Sokoloff joined the faculty at the University of Arizona with similar goals. His practice focuses in the use of robotic and innovative drug therapies to treat men with prostate cancer, the surgical and medical management of complex kidney tumors, and the surgical management of testis cancer. He is actively involved with several national cooperative cancer intergroup that collaborate to perform lathe multi-institution clinical trials and will work closely with colleagues at the University of Arizona to expand the types of surgical procedures and broaden the management strategies offered for patients with urologic cancers.
treatment of prostate, kidney, and testis cancer; robotic surgery
Combining novel and innovative drug therapies with conventional surgery to improve outcomes of patients with aggressive and high-risk, locally advanced and/or metastatic tumors.